Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.64 |
| ▸ | TSHR | P16473 | 6/20 | 0.56 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | BMP1 | P13497 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (Chloromethyl)Benzene SCHEMBL10786903 | 0.91 | ALDH1A1 (0.53) | ALDH1A1TDP1TSHRKAT2BSMN1; SMN2 | |
| SCHEMBL13344110 | 0.85 | TDP1 (0.69) | ALDH1A1TDP1TSHRKAT2BSMN1; SMN2 | |
| SCHEMBL18138442 | 0.83 | TDP1 (0.67) | ALDH1A1TDP1TSHRKAT2BSMN1; SMN2 | |
| SCHEMBL67211 | 0.81 | TDP1 (0.64) | ALDH1A1TDP1TSHRKAT2BSMN1; SMN2 | |
| SCHEMBL31729335 | 0.81 | TDP1 (0.64) | ALDH1A1TDP1TSHRKAT2BSMN1; SMN2 | |
| SCHEMBL66337 | 0.81 | TDP1 (0.64) | ALDH1A1TDP1TSHRKAT2BSMN1; SMN2 | |
| SCHEMBL16958303 | 0.80 | ALDH1A1 (0.62) | ALDH1A1TDP1TSHRKAT2BSMN1; SMN2 | |
| SCHEMBL635089 | 0.80 | ALDH1A1 (1.00) | ALDH1A1TDP1TSHRKAT2BSMN1; SMN2 | |
| SCHEMBL69094 | 0.79 | TSHR (0.53) | ALDH1A1TDP1TSHRSMN1; SMN2CYP3A4 | |
| SCHEMBL5604297 | 0.79 | TSHR (0.69) | ALDH1A1TDP1TSHRSMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0150169-B1 | A PROCESS FOR PREPARING SUBSTITUTED BENZOTRICHLORIDE COMPOUNDS | Monsanto Company (US) | 1987-11-11 | — | — | EP | claimed |
| US-4593144-A | REACTING SUBSTITUTED BENZAL CHLORIDES WITH PRECHLOROALKANE IN PRESENCE OF BASE AND PHASE TRANSFER CATALYST | MONSANTO COMPANY (US) | 1986-06-03 | — | — | US | claimed |
| EP-0150169-A2 | A process for preparing substituted benzotrichloride compounds | Monsanto Company (US) | 1985-07-31 | — | — | EP | claimed |
| US-20250214963-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2025-07-03 | — | — | US | disclosed |
| US-20240109862-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2024-04-04 | — | — | US | disclosed |
| US-20220251066-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2022-08-11 | — | — | US | disclosed |
| US-10450297-B2 | Sulfonyl amide derivatives for the treatment of abnormal cell growth | PFIZER, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20190047979-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER (US) | 2019-02-14 | — | — | US | disclosed |
| US-20170327485-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER (US) | 2017-11-16 | — | — | US | disclosed |
| CN-103951658-B | Sulfamide derivative for treating abnormal cell growth | 辉瑞产品公司 | 2017-10-13 | — | — | CN | disclosed |
| US-20170001981-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER (US) | 2017-01-05 | — | — | US | disclosed |
| EP-0700376-A4 | NITROBENZYL MUSTARD QUATERNARY SALTS AND THEIR USE AS HYPOXIA-SELECTIVE CYTOTOXIC AGENTS | AUCKLAND UNISERVICES LTD (NZ) | 1996-05-22 | — | — | EP | disclosed |
| EP-0700376-A1 | NITROBENZYL MUSTARD QUATERNARY SALTS AND THEIR USE AS HYPOXIA-SELECTIVE CYTOTOXIC AGENTS | AUCKLAND UNISERVICES LIMITED (NZ) | 1996-03-13 | — | — | EP | disclosed |
| WO-1994027954-A1 | NITROBENZYL MUSTARD QUATERNARY SALTS AND THEIR USE AS HYPOXIA-SELECTIVE CYTOTOXIC AGENTS | AUCKLAND UNISERVICES LIMITED (NZ) | 1994-12-08 | — | — | WO | disclosed |
| EP-0150169-B1 | A PROCESS FOR PREPARING SUBSTITUTED BENZOTRICHLORIDE COMPOUNDS | Monsanto Company (US) | 1987-11-11 | — | — | EP | disclosed |
| US-4593144-A | REACTING SUBSTITUTED BENZAL CHLORIDES WITH PRECHLOROALKANE IN PRESENCE OF BASE AND PHASE TRANSFER CATALYST | MONSANTO COMPANY (US) | 1986-06-03 | — | — | US | disclosed |
| EP-0150169-A2 | A process for preparing substituted benzotrichloride compounds | Monsanto Company (US) | 1985-07-31 | — | — | EP | disclosed |
| EP-0000718-B1 | QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS AND THEIR PREPARATION | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1982-03-24 | — | — | EP | disclosed |
| US-4256748-A | INOTROPIC AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1981-03-17 | — | — | US | disclosed |
| EP-0000718-A2 | Quinazoline derivatives, process for their preparation, pharmaceutical preparations and their preparation | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1979-02-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214963-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | ALDH1A1 1427/4885TDP1 4027/4885TSHR 282/4885 |
| US-10450297-B2 | Sulfonyl amide derivatives for the treatment of abnormal cell growth | GPR119, INSR, LYAR | ALDH1A1 1427/4885TDP1 4027/4885TSHR 282/4885 |
| US-20170001981-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | ALDH1A1 1427/4885TDP1 4027/4885TSHR 282/4885 |
| US-20170327485-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | ALDH1A1 1427/4885TDP1 4027/4885TSHR 282/4885 |
| US-20190047979-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | ALDH1A1 1427/4885TDP1 4027/4885TSHR 282/4885 |
| US-20240109862-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | ALDH1A1 1427/4885TDP1 4027/4885TSHR 282/4885 |
| US-20220251066-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | ALDH1A1 1427/4885TDP1 4027/4885TSHR 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.